Rezolute, Inc. Common Stock (NV) RZLT
$3.83
-1.69%
at last close
Market Cap$377.22 million
P/E Ratio—
Div Yield—
Volume87.6K
52-Week Range
$1.07$11.46
Analyst Ratings
- Consensus
- Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $10.13 (+164.1% upside)
Key Stats
- Today's Range
- $3.80 – $3.99
- 50-Day Range
- $3.67 – $5.63
- 52-Week Range
- $1.07 – $11.46
- Volume
- 88K shs
- Average Volume
- 1.70 million shs
- Market Cap
- $377.22 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Rezolute, Inc. Common Stock (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Related Stocks
Compare head-to-head: RZLT vs LLY·RZLT vs JNJ·RZLT vs ABBV·RZLT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.